GlucoTrack (GCTK)
Clinical developer of a knee-pain biologic and implanted glucose monitoring.
Something off on this page? Send us feedback.
Develops LT-100 for knee-osteoarthritis pain and a fully implanted continuous blood glucose monitor, with neither product approved or generating revenue. Clinical development is paired with licensing and co-development partnerships, while Lōkahi controls the public parent and CBGM is held in a separate subsidiary.
Develops two clinical-stage healthcare assets: LT-100, a purified honey-bee-venom biologic for knee-osteoarthritis pain, through Lōkahi Therapeutics, and the Glucotrack CBGM, an implanted continuous blood glucose monitor, through Glucotrack Technologies. The proposed CBGM uses a subcutaneous electronics module and intravascular sensor lead to measure glucose directly from blood and send readings to an external display without a worn transmitter.
Operates from Rutherford, New Jersey, while Lōkahi is in La Jolla, California and recent development activity spans Brazil, Australia, and the United States. Its model combines internal clinical development with asset licensing, co-development, and regional partnerships. Both assets remain precommercial and unapproved in the United States, making progress dependent on clinical results, regulatory decisions, and external partners. Lōkahi controls the public parent, while CBGM remains in a separate wholly owned subsidiary.
Company facts
Categories
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.1M · Total debt $19.0K · Total assets $1.5M · Shareholders' equity −$1.7M
- Revenue
- $0
- Operating income
- −$3.4M
- Net income
- −$3.8M
No dividends on record.
| Institutions12 holders · as of Mar 31, 2026 | 1.51% | 10.7K shares | |
| Insiders7 holders · as of Oct 7, 2025 | 0.57% | 4.0K shares | |
| Strategic holders1 holder · as of Mar 31, 2025 | 0.43% | 3.0K shares | |
| Otherremainder | 97.49% | 687.5K shares |
705.3K company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (705.3K in the company's Sep 3, 2026 report, 798.1K elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
John BallantyneInsiderdirector, 10 percent owner | 0.46% | 3,256 | Form 4filed Mar 31, 2025 ↗ |
Geode Capital Management, LLCInstitution | 0.44% | 47,001 | 13Fas of Mar 31, 2026 |
Ikarian Capital, LLCInstitution | 0.43% | 45,830 | 13Fas of Mar 31, 2026 |
John A. Ballantyne Revocable Living Trust dated 08/01/2017Strategic10 percent owner | 0.43% | 3,048 | Form 4filed Mar 31, 2025 ↗ |
HRT Financial LPInstitution | 0.38% | 40,631 | 13Fas of Mar 31, 2026 |
| See all 24 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Abbott
FreeStyle Libre 3 leads a scaled transcutaneous CGM alternative.
- Dexcom
Dexcom G7 offers a scaled real-time CGM alternative.
- Medtronic
Guardian CGM links glucose sensing with insulin delivery.
- Senseonics
Eversense 365 is the closest commercial implantable CGM.
- Anika Therapeutics
Injectable OA-pain therapies overlap with LT-100's treatment goal.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| GlucoTrack | $3.56 | +0.99% | $2.8M | — | — | — | — |
| Abbott | $111.49 | +0.93% | $191.19B | 35.5 | 19.0 | 4.1 | +13.0% |
| Dexcom | $89.59 | −0.11% | $33.85B | 35.5 | 32.0 | 6.8 | +13.1% |
| Medtronic | $92.40 | +0.22% | $118.00B | 22.7 | 15.3 | 3.1 | +13.7% |
| Senseonics | $10.28 | +3.52% | $415.4M | — | — | 8.6 | +118.1% |
| Anika Therapeutics | $21.58 | +2.23% | $288.4M | — | 35.1 | 2.4 | +15.6% |
| Median | 35.5 | 25.5 | 4.1 | +13.7% |